Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,092.00 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 22,184 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $0.50, for a total transaction of $11,092.00. Following the transaction, the director owned 1,104,312 shares in the company, valued at approximately $552,156. The trade was a 1.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total transaction of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $28,336.50.
• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $22,745.16.
• On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total transaction of $214,018.70.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total transaction of $9,659.10.
• On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $4,733.40.
• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total transaction of $34,533.36.
• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $42,627.62.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $0.44 on Friday. The firm’s 50-day simple moving average is $0.78 and its 200-day simple moving average is $0.78. Werewolf Therapeutics, Inc. has a twelve month low of $0.40 and a twelve month high of $2.38. The firm has a market cap of $21.56 million, a P/E ratio of -0.36 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. On average, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics in the first quarter valued at about $79,000. Marshall Wace LLP acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at $113,000. Qube Research & Technologies Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at $48,000. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics in the second quarter valued at about $409,000. Finally, Bank of America Corp DE raised its holdings in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HOWL. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Werewolf Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.